アトピー性皮膚炎治療薬の市場規模は2022年に152億ドルと評価されました。この市場は、2023年の169億ドルから2032年までに408億1000万ドルに成長し、予測期間中のCAGRは11.60%になると予測されます。世界中の人口におけるアトピー性皮膚炎 (AD) の発生率の増加、病気の治療法の利用可能性に関する人々の意識の高まり、およびより良い、より手頃な価格の治療を提供するために政府が実施する取り組みの強化が、アトピー性皮膚炎治療市場の重要な推進要因になると予想されます。
目次
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS
6.1. Overview
6.2. Biologics
6.3. PDE4 Inhibitors
7. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1. Overview
7.2. Topical
7.3. Injectable
7.4. Oral
8. GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America
9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Atopic Dermatitis Treatment Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Atopic Dermatitis Treatment Market,
9.7. Key developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2022
9.8.2. Major Players R&D Expenditure. 2022
10. COMPANY PROFILES
10.1. AbbVie Inc
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. ARCUTIS BIOTHERAPEUTICS, INC
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Asana Biosciences, Inc
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Astellas Pharma, Inc.
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Bayer AG, Inc
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. BRISTOL-MYERS SQUIBB INC
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Dermavant Sciences, Inc
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. ELI LILLY AND COMPANY, INC
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Galderma, Inc
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. INCYTE CORPORATION, INC
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 7 US: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 8 US: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 9 CANADA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 10 CANADA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 11 EUROPE: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 12 EUROPE: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 13 GERMANY: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 14 GERMANY: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 15 FRANCE: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 16 FRANCE: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 17 ITALY: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 18 ITALY: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 19 SPAIN: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 20 SPAIN: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 21 UK: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 22 UK: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 23 REST OF EUROPE: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 24 REST OF EUROPE: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 25 ASIA-PACIFIC: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 26 ASIA-PACIFIC: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 27 JAPAN: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 28 JAPAN: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 29 CHINA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 30 CHINA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 31 INDIA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 32 INDIA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 33 AUSTRALIA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 34 AUSTRALIA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 35 SOUTH KOREA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 36 SOUTH KOREA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 37 REST OF ASIA-PACIFIC: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 38 REST OF ASIA-PACIFIC: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 39 REST OF THE WORLD: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 40 REST OF THE WORLD: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 41 MIDDLE EAST: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 42 MIDDLE EAST: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 43 AFRICA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 44 AFRICA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
TABLE 45 LATIN AMERICA: ATOPIC DERMATITIS TREATMENT MARKET, BY DRUG CLASS, 2018-2032 (USD BILLION)
TABLE 46 LATIN AMERICA: ATOPIC DERMATITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ATOPIC DERMATITIS TREATMENT MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ATOPIC DERMATITIS TREATMENT MARKET
FIGURE 4 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY DRUG CLASS, 2022
FIGURE 5 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2022
FIGURE 6 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 7 NORTH AMERICA: ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 EUROPE: ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 ASIA-PACIFIC: ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 REST OF THE WORLD: ATOPIC DERMATITIS TREATMENT MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 GLOBAL ATOPIC DERMATITIS TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 12 ABBVIE INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 ABBVIE INC: SWOT ANALYSIS
FIGURE 14 ARCUTIS BIOTHERAPEUTICS, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 ARCUTIS BIOTHERAPEUTICS, INC: SWOT ANALYSIS
FIGURE 16 ASANA BIOSCIENCES, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 ASANA BIOSCIENCES, INC: SWOT ANALYSIS
FIGURE 18 ASTELLAS PHARMA, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 ASTELLAS PHARMA, INC: SWOT ANALYSIS
FIGURE 20 BAYER AG, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 BAYER AG, INC: SWOT ANALYSIS
FIGURE 22 BRISTOL-MYERS SQUIBB INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 BRISTOL-MYERS SQUIBB INC: SWOT ANALYSIS
FIGURE 24 DERMAVANT SCIENCES, INC. : FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 DERMAVANT SCIENCES, INC. : SWOT ANALYSIS
FIGURE 26 ELI LILLY AND COMPANY, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 ELI LILLY AND COMPANY, INC: SWOT ANALYSIS
FIGURE 28 GALDERMA, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 GALDERMA, INC: SWOT ANALYSIS
FIGURE 30 INCYTE CORPORATION, INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 INCYTE CORPORATION, INC: SWOT ANALYSIS
